Lipocine Inc

Lipocine Inc. is a clinical-stage biopharmaceutical company that researches and develops drug delivery using its proprietary technology. Its product portfolio includes TLANDO, an oral testosterone replacement therapy, and several candidates in clinical trials for conditions such as postpartum depression, decompensated cirrhosis, recurrent preterm birth, non-alcoholic steatohepatitis, obesity management, major depressive disorders, essential tremor, and epilepsy. The company focuses on neurological and psychiatric central nervous system disorders, liver disease, and hormone supplementation in the United States. Founded in 1997, Lipocine is headquartered in Salt Lake City, Utah, and collaborates with Verity Pharmaceuticals to develop and commercialize TLANDO and TLANDO XR.

LPCN▲

Lipocine Appoints Michael J. Grissinger to Board of Directors

Lipocine Inc. has appointed Michael J. Grissinger to its Board of Directors, effective August 3, 2026. Grissinger brings over two decades of experience from Johnson & Johnson, where he held senior roles including Vice President and Head of Worldwide Pharmaceutical Licensing and Vice President and Head of Worldwide Pharmaceutical Corporate Development and M&A. He currently serves on the boards of Aprea Therapeutics and Adicet Bio. Lipocine Chairman Dana Ono stated that Grissinger's dealmaking experience will be invaluable as the company advances its pipeline and pursues partnerships. Grissinger noted the company's innovative oral delivery technology and its portfolio of commercial and late-stage clinical assets.

LPCN ▲

PR Newswire·46dRead more →